We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01095510
Recruitment Status : Completed
First Posted : March 30, 2010
Results First Posted : July 25, 2014
Last Update Posted : August 5, 2015
Sponsor:
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Hereditary Angioedema
Intervention: Biological: CINRYZE

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were not enrolled in the lower body weight category (10-25 kilograms [kg]) 1000 Units (U) dose group despite substantial recruitment efforts.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of 12 participants screened, 9 participants were enrolled and treated. The reason for 3 participants were screen failures as they did not meet the inclusion criteria.

Reporting Groups
  Description
500 U CINRYZE (10-25 kg Body Weight) Single intravenous (IV) dose of 500 U CINRYZE
1000 U CINRYZE (10-25 kg Body Weight) Single IV dose of 1000 U CINRYZE
1000 U CINRYZE (>25 kg Body Weight) Single IV dose of 1000 U CINRYZE
1500 U CINRYZE (>25 kg Body Weight) Single IV dose of 1500 U CINRYZE

Participant Flow:   Overall Study
    500 U CINRYZE (10-25 kg Body Weight)   1000 U CINRYZE (10-25 kg Body Weight)   1000 U CINRYZE (>25 kg Body Weight)   1500 U CINRYZE (>25 kg Body Weight)
STARTED   3   0   3   3 
COMPLETED   3   0   3   3 
NOT COMPLETED   0   0   0   0 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
500 U CINRYZE (10-25 kg Body Weight) Single IV dose of 500 U CINRYZE
1000 U CINRYZE (>25 kg Body Weight) Single IV dose of 1000 U CINRYZE
1500 U CINRYZE (>25 kg Body Weight) Single IV dose of 1500 U CINRYZE
Total Total of all reporting groups

Baseline Measures
   500 U CINRYZE (10-25 kg Body Weight)   1000 U CINRYZE (>25 kg Body Weight)   1500 U CINRYZE (>25 kg Body Weight)   Total 
Overall Participants Analyzed 
[Units: Participants]
 3   3   3   9 
Age 
[Units: Years]
Median (Full Range)
 7 
 (6 to 9) 
 9 
 (7 to 9) 
 10 
 (8 to 11) 
 9 
 (6 to 11) 
Gender 
[Units: Participants]
       
Female   3   3   2   8 
Male   0   0   1   1 
Region of Enrollment 
[Units: Participants]
       
United States   3   3   3   9 


  Outcome Measures

1.  Primary:   Presence of Unequivocal Beginning of Relief of the Defining Attack Symptom   [ Time Frame: Within 4 hours following treatment ]

2.  Secondary:   Time to Unequivocal Beginning of Relief of the Defining Attack Symptom   [ Time Frame: Within 4 hours following treatment ]

3.  Secondary:   Time to Complete Resolution of the Attack   [ Time Frame: Within 1 week following treatment ]

4.  Secondary:   Change in C1 Inhibitor (C1 INH) Antigen and Functional C1 INH Concentrations   [ Time Frame: Pre-dose, 2, 4, 8 hours post dose on Day 1; Day 2, 3, 5, 8 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Change in C1 INH antigen and functional C1 INH concentrations endpoint was not analyzed as no participants agreed to additional and optional blood sampling. As a result, no PK parameters were calculated for this study.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Jennifer Schranz, MD
Organization: Shire
phone: 484-595-8940
e-mail: jschranz@shire.com



Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01095510     History of Changes
Other Study ID Numbers: 0624-203
2011-000369-11 ( EudraCT Number )
First Submitted: March 24, 2010
First Posted: March 30, 2010
Results First Submitted: June 26, 2014
Results First Posted: July 25, 2014
Last Update Posted: August 5, 2015